Dextromethorphan/quinidine

Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA). It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.
Dextromethorphan/quinidine was approved for medical use in the United States in October 2010, and is marketed by Avanir Pharmaceuticals.
Medical uses
DXM/quinidine is used in the treatment of PBA. In a 12-week randomized, double-blind trial, amyotrophic lateral sclerosis and multiple sclerosis patients with significant PBA were given either Nuedexta 20/10 mg or placebo. In 326 randomized patients, the PBA-episode daily rate was 46.9% (p < 0.0001) lower for Nuedexta than for placebo. The three deaths in each of the two drug treatment arms and the single death in the placebo arm of the study were believed to be due to the natural course of the disease.
Contraindications
Atrioventricular (AV) block, complete, without implanted pacemaker or at high risk of complete AV block
Concomitant use with drugs containing quinidine, quinine, or mefloquine
Concomitant use with drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide); effects on QT interval may be increased
Concomitant use with MAOIs or use of MAOIs within 14 days; risk of serious, potentially fatal, drug interactions including serotonin syndrome
Heart failure
Hypersensitivity to dextromethorphan
Hypersensitivity to quinine, mefloquine, quinidine, or dextromethorphan/quinidine with a history of thrombocytopenia, hepatitis, bone marrow depression or lupus-like syndrome induced by these drugs
QT interval, prolonged or congenital long QT syndrome or a history suggesting torsades de pointes
Adverse effects
Common risks and side effects include:
Abdominal pain
Asthenia
Cough
Diarrhea (reported in 13% of patients)
Dizziness
Elevated gamma glutamyltransferase
Flu-like symptoms
Flatulence
Prolonged QT interval
Muscle spasm
Peripheral edema
Urinary tract infection
Vomiting
Interactions
Desipramine (CYP2D6 substrate) levels increase 8-fold with co-administration
Paroxetine (CYP2D6 inhibitor and substrate)
Memantine
Pharmacology
Pharmacodynamics
Dextromethorphan acts as a σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor, and NMDA receptor antagonist, while quinidine is an antiarrhythmic agent acting as a CYP2D6 inhibitor. Quinidine prevents the metabolism of dextromethorphan into its active metabolite dextrorphan, which is a much more potent NMDA receptor antagonist but much less potent serotonin reuptake inhibitor than dextromethorphan. The mechanism of action of dextromethorphan/quinidine in the treatment of PBA is unknown.
Research
Dextromethorphan/quinidine was investigated for the treatment of agitation associated with dementia, diabetic neuropathy, drug-induced dyskinesia, migraine, and neuropathic pain, but development for these indications was discontinued. Another formulation, deudextromethorphan/quinidine, is still under investigation for various indications. These include agitation, schizophrenia, and major depressive disorder, among others.
See also
Bupropion/dextromethorphan
Deudextromethorphan/quinidine
References
External links
Combination drugs
Otsuka Pharmaceutical